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Highlights 
 Superior control in the bioreactor led to improved hMSC quality, consistency and yield  
 At 25% dissolved oxygen in serum-free media, there was a 500 % increase in the hMSC yield 
 Process control significantly reduced the variation in hMSC yield to < 15%  
 
Abstract 
Human Mesenchymal Stem Cells (hMSCs) are advancing through clinical development with the first 
allogeneic adult hMSC therapy receiving approval in Europe. To enable successful large-scale 
manufacture of hMSC therapies, increased product consistency and yield, and a reduced batch-to-
batch variation must be achieved. This paper addresses ways to reduce variation by controlling the 
processing conditions, in particular the dissolved oxygen concentration (dO2), and the culture medium. 
Bone marrow derived hMSCs were cultured in DASGIP DASbox bioreactors on Plastic P-102L 
microcarriers in FBS-containing and serum free (SFM) media at various dO2 values from 100% to 10%, 
experiencing the same dO2 value throughout the culture process. The superior control of pH and dO2 
in the bioreactor led to improved performances compared to poorly controlled spinner flasks, 
particularly at reduced dO2 concentrations. At 25% dO2, there was a 300 % increase in the BM-hMSC 
yield in the bioreactor across the two donor BM-hMSCs in SFM compared to FBS-containing medium. 
Overall, the process yield increased by an average of around 500% for both donors under controlled 
conditions in SFM at 25% dO2 in the bioreactor compared to the poorly controlled expansion at 
atmospheric conditions in FBS-containing medium in spinner flasks. Process control significantly 
reduced the BM-hMSC variation in yield from 79.1% in FBS-containing medium in spinner flasks to < 
15% in controlled SFM bioreactor culture.   
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1. Introduction 
Bone marrow-derived human mesenchymal stem cells (BM-hMSCs) have generated much interest in 
the field of regenerative medicine (RM), with the potential to treat and in some cases, cure human 
disease. This interest has been largely driven by their ability to proliferate under appropriate culture 
conditions and their capacity to secrete a range of trophic factors which regulate host immune 
response and initiate tissue repair [1]. Consequently, hMSCs are advancing through clinical 
development targeting indications such as cardiac repair, neurological disease and immune disorders 
[2]. This progress is exemplified by the first allogeneic adult mesenchymal stem cell therapy to receive 
central marketing authorization approval in Europe [3]. 
 
The addition of microcarriers has been used to culture adherent cells such as BM-hMSCs in suspension 
[4] allowing for process scale-up, where online monitoring and control systems can be used to deliver 
a consistent and cost-effective BM-hMSC therapy. Further to this, stirred-suspension bioreactors are 
currently employed in biopharmaceutical production and therefore their design and operation are 
well-understood [5], with the potential to meet the expected manufacturing demands of large-scale 
BM-hMSC therapies [6]. The use of serum-free medium with microcarriers for the expansion of BM-
hMSCs has previously been demonstrated for uncontrolled processes [7-9] and therefore represents a 
viable alternative for large-scale serum free manufacture of BM-hMSCs.  
 
One of the key aspects of a successful manufacturing process is in the reduction of product variation, 
which is particularly challenging when the cell is the final product. Variation can be introduced into the 
product by both the process input material and the process conditions [10]. The input to the process 
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must be controlled by strict BM-hMSC isolation techniques and potentially cell selection steps to 
improve product input consistency [11], although appropriate isolation methods are typically poorly 
defined for BM-hMSCs. The US Food and Drug Administration (FDA) has released guidance documents 
on the use of process control and real time release testing for pharmaceutical manufacturing [12]. This 
guidance has highlighted the importance regulators are placing on continual manufacturing process 
improvement and enhanced understanding as a fundamental aspect of manufacturing development 
and control. Process analytical technology or PAT is a system for analyzing and controlling 
manufacturing processes through measurement of product attributes to ensure final product quality, 
proposed by the FDA [13]. It will therefore be desirable to utilize these PAT technologies and measure 
online parameters in order to develop control systems to ensure that the product characteristics 
remain consistent. These relevant process parameters are likely to include a combination of cell 
growth, medium temperature, pH, pO2 and pCO2, which are commonplace in current 
biopharmaceutical production processes [14]. 
 
Of these parameters, the level of dO2 is the one that is usually of most concern when cultivating cells 
in bioreactors [15]. With respect to BM-hMSCs, our earliest work conducted in an oxygen-controlled 
incubator for both monolayer [16] and spinner flask culture [17] indicated that with the same donor 
cells as cultured here, the performance with respect to growth kinetics was better at 100% dO2 than 
at lower values when cultured over 3 passages. Whilst some researchers have also shown 100% dO2 
gives enhanced growth kinetics, others have found that lower dO2 values [17] are advantageous. Much 
of that early literature, including our own studies, did not offer very close control of dO2 in the actual 
medium in which the cells are growing. Therefore, it was hypothesized that this rather loose control 
might account for the literature differences, always recognizing too that it might be associated with 
cell to cell variability. However, very tight dO2 control can be achieved by an in-situ dO2 probe 
throughout the culture in the closed environment offered by a bioreactor. Therefore, it was decided to 
investigate the effect of dO2 on culture as a major part of this study.   
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Thus, whilst the impact of dO2 is a major feature, the overall aim is to develop a process control strategy 
for the microcarrier culture of BM-hMSCs in suspension to drive increased consistency and yield into 
the process. The impact of this process control strategy on process economics and product consistency 
will also be assessed here for two BM-hMSC donors in both FBS-based and serum-free medium and 
compared to previously developed, loosely controlled monolayer and microcarrier-based suspension 
BM-hMSC expansion processes [8].  Of course, agitation intensity and aeration strategy (sparged, with 
or without protective surfactants, or headspace) are also relevant and these aspects have also been 
addressed for the same cells elsewhere [18].  
 
 
2. Materials & Methods 
2.1 Monolayer Culture 
BM-hMSCs were isolated from bone-marrow aspirate purchased from Lonza (Walkersville, USA) 
obtained from two healthy donors with informed consent; BM-hMSC 1 (lot: 071313B) and BM-hMSC 
2 (lot: 071281D).  The local Ethical Committee approved the use of the sample for research.  Cells from 
passage 1 were cryopreserved at a density of 1-2 x 106 cells.ml-1 in a freeze medium containing 90% 
(v/v) FBS (Hyclone, Belgium) and 10% (v/v) dimethylsulphoxide (Sigma-Aldrich, UK). Prior to the 
experimental work, cells were grown in T-flasks seeded at 5,000 cells.cm-2 at 37°C in humidified air 
(100% dissolved oxygen, dO2) containing 5% CO2. For serum-free culture, the growth surface of T-flasks 
was coated with 0.4 µg.cm-2 PRIME-XV human fibronectin (FN) (Irvine Scientific, USA) and cultured in 
PRIME-XV MSC Expansion SFM (Irvine Scientific, USA) as per manufacturer’s instructions. On passage, 
the hMSCs were washed with phosphate buffered saline without Ca+ or Mg+ (PBS) and incubated for 4 
min with TrypLE Express (Invitrogen, UK). Dissociation reagents were inactivated by the addition of 
appropriate growth medium and the cell suspension was centrifuged at 220g for 5 min. The 
supernatant was discarded, and the remaining pellet was re-suspended in an appropriate volume of 
AC
CE
PT
ED
 M
AN
US
CR
IPT
6 
 
culture medium. BM-hMSCs underwent one adaptation passage in serum-free medium, prior to 
experimental work taking place.    
 
2.2 DASGIP DASbox bioreactor microcarrier culture 
The glass surfaces of 250 ml DASGIP DASbox bioreactors (diam. T = 60 mm) (Eppendorf, Germany) 
were siliconized with Sigmacoat (Sigma-Aldrich, UK) according to manufacturer’s instructions.  The 
bioreactors were equipped with a 3-blade 30°-pitch, down pumping impeller (diameter, D = 30.25 
mm), a temperature probe, a Hamilton dO2 probe, a Hamilton pH probe, an off-gas analyser and two 
sterile sample ports. Solid, non-porous Plastic P-102L microcarriers of 160-200 microns (Solohill, USA) 
were prepared at 500 or 1000 cm2 following manufacturer’s instructions. Extensive physical 
characterization of these Plastic P-102L microcarriers and 18 other commercially available 
microcarriers has been performed previously by our group [19]. In addition, culture of hMSCs on each 
of them was undertaken and the SoloHill Plastic P-102L microcarrier was selected as the optimal 
microcarrier based on the following criteria, (i) extent of cell proliferation on the microcarrier, (ii) 
amenability for xeno-free processing and (iii) the ability to effectively harvest the cells from the 
microcarrier without any detrimental effect on cellular immunophenotype and differentiation 
capacity. They have since been shown to perform consistently well in our studies [20]. 
 
Microcarriers were or coated with 0.1 µg.cm-2 PRIME-XV FN prior to hMSC inoculation at 6,000 
cells.cm-2 and cultured in 100 mL of either Dulbecco’s Modified Eagle Medium (DMEM; Lonza, UK) 
supplemented with 10 % (v/v) foetal bovine serum (FBS) (Lot: RVC35874, Hyclone, Belgium) and 2 mM 
ultraglutamine (Lonza, UK), or PRIME-XV MSC Expansion SFM with bioreactor control set-points of 37 
°C and pH 7.4. As discussed earlier, various dissolved oxygen concentrations (dO2) were used as set out 
in detail below. A 50 % medium exchange was performed every two days as per manufacturer’s 
instructions, with fresh culture medium equilibrated to the appropriate dO2, temperature and pH using 
a controlled bioreactor vessel on the DASGIP system prior to medium exchange. Following inoculation, 
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the culture was static for one hour, after which the culture was agitated constantly at the minimum 
rate for just complete suspension of microcarriers (NJS) found to be 115 rpm as recommended 
previously [2, 3, 4], with daily medium and cell-microcarrier samples of 1 mL taken for analysis. The 
DASbox system was set up, calibrated and controlled using the DASGIP DASbox control unit (Eppendorf, 
Germany) and was operated with headspace aeration to achieve sufficient gas supply, which gave good 
dO2 control.  
 
2.3 DASGIP DASbox bioreactor harvest 
BM-hMSCs were harvested using a method previously developed by us [21, 22]. Briefly, the DASbox 
control was switched off and the microcarriers allowed to settle. The spent culture medium was 
removed and the microcarriers were washed twice in 50 ml of Ca2+ and Mg2+ free PBS. The PBS was 
removed before adding 80 mL of TrypLE Express dissociation reagent for 10 minutes at an impeller 
speed of 375 rpm (ending with 5 seconds at 400 rpm). The dissociation reagent was then quenched 
with 70 ml of culture medium and a 2 mL sample placed in a single well of a 6 well plate for analysis 
under a light microscope to assess cell detachment. The remainder of the solution was filtered through 
a 60 μm Steriflip Filter Unit (Merck Millipore, Germany) to separate the microcarriers from the BM-
hMSCs. The cell suspension was centrifuged, the supernatant aspirated and the cell pellet re-
suspended in culture medium. A cell count was then performed using a NucleoCounter NC-3000 to 
assess the overall hMSC growth and the culture harvest efficiency.  
 
2.4 Spinner flask culture and harvest 
Full details of this aspect have been published previously [7]. In essence, the culture was undertaken 
in 100 mL spinner flasks (BellCo, USA) in an incubator in the presence of ambient air with the same 
type and concentration of microcarriers, with the cell concentration used in the bioreactor. All other 
conditions were also as in the bioreactor except that the agitation speed, NJS, was 30 rpm.  Daily 
medium samples of 1mL taken for analysis. BM-hMSCs were harvested using the same previously 
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developed method [21, 22] as in the bioreactor, except that the agitation speed was 150 rpm for 7–10 
min and 250 rpm for the final few seconds. More details are given elsewhere [7]. 
 
 
2.5 Analytical Techniques 
Analysis of glucose and lactate concentrations in the spent medium was performed using a Cedex Bio-
HT (Roche, Germany). Cell counting, mean cell diameter and viability (via acridine orange uptake and 
DAPI exclusion) was performed using a NucleoCounter NC-3000 automated mammalian cell counter 
(Chemometec, Denmark). The following parameters were obtained: 
1. Specific Growth Rate 
𝑆𝑝𝑒𝑐𝑖𝑓𝑖𝑐 𝑔𝑟𝑜𝑤𝑡ℎ 𝑟𝑎𝑡𝑒, µ =  
ln(
𝐶𝑥(𝑡)
𝐶𝑥(0)
⁄ )
∆𝑡
  
where µ is the net specific growth rate (h-1), Cx(t) and Cx(0) are the cell numbers at the end and start 
of the exponential growth phase, respectively and t is time (h).  
2. Population Doublings 
𝑃𝑜𝑝𝑢𝑙𝑎𝑡𝑖𝑜𝑛 𝐷𝑜𝑢𝑏𝑙𝑖𝑛𝑔𝑠, 𝑃𝑑 =
1
log  (2)
∙ log (
𝐶𝑥(𝑡)
𝐶𝑥(0)
)  
where Pd is the number of population doublings, Cx(t) and Cx(0) are the cell numbers at the end and 
start of the exponential growth phase, respectively. 
3. Specific Metabolite Consumption/Production Rate 
𝑆𝑝𝑒𝑐𝑖𝑓𝑖𝑐 𝑚𝑒𝑡𝑎𝑏𝑜𝑙𝑖𝑡𝑒 𝑓𝑙𝑢𝑥, 𝑞𝑚𝑒𝑡 = (
𝜇
𝐶𝑥(0)
) ∙ (
𝐶𝑚𝑒𝑡(𝑡)−𝐶𝑚𝑒𝑡(0)
𝑒𝜇𝑡−1
)  
where qmet is the net specific metabolite consumption or production rate, µ is the specific growth rate 
(h-1), Cx(0) is the cell number at the end of the exponential growth phase, Cmet(t) and Cmet(0) are the 
metabolite concentrations at the end and start of the exponential growth phase, respectively and t is 
time (h).  
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4. Inter- and intra-donor coefficient of variation 
𝑐𝑣 =
𝜎
𝜇
 
where cv is the coefficient of variation, σ is the standard deviation of the Relative Process Yield for each 
experimental run and each hMSC donor, and μ is the average (mean) of the Relative Process Yield for 
each experimental run and each hMSC donor. 
 
2.6 Colony-forming unit fibroblast (CFU-f) Efficiency 
To assess the CFU-f efficiency, BM-hMSCs were seeded in a T-flask at 10 cells.cm-2 and cultured with a 
medium exchange every 3-5 days. Following 14 days culture, cells were washed with PBS and fixed in 
4% formaldehyde (v/v) (Sigma, UK) for 30 minutes. Colonies were stained with 1% crystal violet (Sigma, 
UK) in 100% methanol (w/v) for 30 minutes. Stained colonies that were made up of more than 25 cells 
were recorded as CFUs. 
 
2.7 hMSC Characterization 
Immunophenotype analysis was performed by multiparameter flow cytometry before and after the 
hMSC expansion process using a previously developed protocol [23]. Morphology images were 
obtained using a light microscope (Nikon Eclipse TS-100, UK). 
 
The hMSC differentiation was induced using PRIME-XV Differentiation SFM (Irvine Scientific, USA) as 
per manufacturer’s instructions. After 21 days the differentiation medium was removed, cells rinsed 
with PBS then fixed with 4% (v/v) PFA at room temperature. Adipocytes were stained with 1% (w/v) 
Oil Red O (Sigma-Aldrich, UK) in isopropanol at room temperature and rinsed with distilled water. 
Osteoblasts were incubated with 2.5% (v/v) silver nitrate (Sigma-Aldrich, UK) under ultraviolet light (30 
minutes exposure), rinsed with distilled water and stained with fast violet solution (Sigma-Aldrich, UK) 
containing 4% (v/v) napthol AS-MX phosphate alkaline (Sigma-Aldrich, UK) for 45 minutes at room 
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temperature in the dark. Chondrocytes were stained with 1% (w/v) Alcian blue (Sigma-Aldrich, UK) in 
0.1 M hydrochloric acid (Sigma-Aldrich, UK). After 30 minutes incubation, cells were rinsed three times 
with 0.1 M HCl. After staining, differentiated cells were visualized under a light microscope (Nikon 
Eclipse TS-100, UK). Previously published short tandem repeat analysis of these two BM-hMSC lines 
showed a retention of the characteristic genotype of BM-hMSCs throughout an extended culture 
process [24]. 
 
2.8 Statistical Analysis  
Results were deemed to be signiﬁcant if p < 0.05 using an unpaired two-tailed Students t-test. 
 
 
3. Results & Discussion 
3.1 Effect of dissolved oxygen concentration on BM-hMSC expansion on microcarriers 
Dissolved oxygen concentration has been previously shown to have an impact on BM-hMSC growth 
and cell characteristics [25], with much debate around the use of the terms “normoxia” (100 % dO2) 
and “hypoxia” (typically < 25 % dO2) [16]. Almost all of the current technology for BM-hMSC expansion 
utilize open, laboratory scale processes such as T-flasks (or occasionally spinner flasks) wherein 
controlling, monitoring, and evaluating the impact of key parameters on target cell output and 
productivity is difficult [26]. Control of process parameters such as dissolved oxygen during the 
manufacturing process will be vital in maximizing product consistency and ensuring that the process 
is scalable. A large part of this ability to control the process conditions is in maintaining a closed process 
during expansion, which not only reduces contamination risk but is vital in maintaining the desired 
culture environment of the BM-hMSCs and avoid fluctuations in these critical process parameters. 
Much of the current literature on low oxygen culture of BM-hMSC use hypoxic incubators that maintain 
a low oxygen environment (an oxygen concentration in the gas phase lower than that found in 
atmospheric air) rather than controlling the dO2 conditions in the actual bioreactor medium in T-flasks 
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(or spinner flasks), with process manipulations taking place within the atmospheric oxygen 
concentrations.  
Figure 1 shows the impact of exposing low dissolved oxygen (dO2) experiments to atmospheric oxygen 
within an agitated bioreactor process simulating the exposure to such conditions during culture 
involving media exchange when using hypoxic incubators. This figure demonstrates that for a dO2 set-
point of 5 % (1.05 % atmospheric oxygen), after a one-hour exposure of the culture to atmospheric 
conditions (21 % atmospheric oxygen equivalent to 100 % dissolved oxygen at saturation), creates a 
deviation to a maximum dO2 concentration of 77.9 %, which takes a further 294 minutes to return to 
5 % dO2 with continual headspace aeration with 1.05% atmospheric oxygen. Considering the number 
of manipulations that occur during culture, for example, daily sampling and medium exchange, this 
mode of operation causes large and prolonged fluctuations in dissolved oxygen concentrations 
experienced by the BM-hMSCs. This experiment has taken place in agitated conditions with headspace 
aeration, which represents a best-case scenario, as in static monolayer culture without headspace 
gassing these deviations in dO2 would be larger with an increased set-point recovery time. It is 
suggested that this variation in dO2 during processing is a potential reason why there is so much 
discrepancy within the published literature of BM-hMSCs cultured in low oxygen concentration 
atmospheres, with some groups suggesting that the optimal BM-hMSC culture condition occurs when 
the cells are never exposed to atmospheric oxygen levels, even during the initial isolation and banking 
phase [27]. In addition, of course, when “normoxic” (21 % atmospheric oxygen) is used, such variations 
do not occur.  
Figure 2A shows the effect of various controlled dissolved oxygen concentrations on BM-hMSC 1 
growth on microcarriers over six days of culture in FBS-containing medium, with increased growth 
kinetics at lower dissolved oxygen concentrations where each dO2 value was held constant throughout 
that time by performing culture sampling and medium exchange without exposing the culture to 
atmospheric conditions. This effect of dO2 is confirmed by Figure 2B, which shows the post-harvest cell 
AC
CE
PT
ED
 M
AN
US
CR
IPT
12 
 
number at each dO2 concentration, with significantly higher BM-hMSC numbers (p < 0.05) at 10 and 
25 % dO2 compared with 100 % dO2. There is currently no common consensus in the literature on 
whether low oxygen concentrations are beneficial for BM-hMSCs, with some studies demonstrating 
improved growth [28] and function [29], whilst others, including our previously published work, 
demonstrates diminished BM-hMSC characteristics [16] in uncontrolled monolayer culture. These 
results suggest that for these donor cells (BM-hMSC 1), BM-hMSC growth characteristics are improved 
at low dissolved oxygen concentrations, when undertaken in a fully dO2 controlled microcarrier 
expansion process. More work of this type with fully controlled dO2 is required to establish whether 
low values are generally beneficial for BM-hMSC culture. 
It is again important to assess the effect of changing dO2 concentrations on the relative metabolite flux 
of the BM-hMSC during microcarrier expansion. Supplementary figure 1 shows the concentrations of 
glucose, lactate and ammonia over the six days of expansion, with increased consumption of glucose 
and production of lactate in low dissolved oxygen concentrations, in accordance with the increased 
BM-hMSC growth rate. The production of ammonia in 10 and 25 % dO2 was reduced compared with 
higher dO2 concentrations, despite the increased BM-hMSC number at the lower dissolved oxygen 
concentration. The LDH and total protein concentrations have been measured to assess whether any 
BM-hMSC stress or damage has been caused by the different dO2 concentrations, which did not change 
significantly through culture in any of the conditions (supplementary figure 2). The per cell flux of 
ammonia and the yield of lactate from glucose can be seen in figure 2A and 2B respectively for BM-
hMSC 1 culture on microcarriers at various controlled dO2 concentrations. The per cell flux of ammonia 
in figure 2A shows a significant reduction (p < 0.05) for both 25 and 10 % dO2 to around 2.5 pmol.cell-
1.day-1, compared to 100 % dO2. These findings are again in agreement with a previous study [28] and 
suggests a more efficient cell metabolism under low dO2 culture conditions. A reduction in the 
production in ammonia at low dO2 concentrations for microcarrier culture is also advantageous for 
process operation, as the build-up of toxic compounds to inhibitory levels will become less of an issue 
[30]. The yield of lactate production from glucose can be seen in figure 2B, which shows a reduction in 
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yield to 1.21 ± 0.37 mol.mol-1 at 25% dO2, but a subsequent increase at 10 % dO2 to 2.27 ± 0.26 
mol.mol-1 compared with 100 % dO2. This result is in agreement with studies of BM-hMSC culture at 
low oxygen concentrations in monolayer involving BM-hMSCs [16, 28] but is significantly higher than 
BM-hMSCs derived from the umbilical cord at both high and low dO2 concentrations [31]. Considering 
the importance of the in vivo niche environment on hMSC characteristics, it is possible that this 
difference in cell metabolism at different dissolved oxygen concentrations is due to relative differences 
in the in vivo oxygen concentrations in the bone-marrow and umbilical cord tissues [32]. This difference 
may also help explain the varying results in the literature. 
 
It is also important to assess whether microcarrier expansion at reduced dO2 concentrations is not 
unduly affecting the post-harvest BM-hMSC characteristics, despite the improved growth kinetics seen 
previously. Figure 3A shows the outgrowth rate of BM-hMSC 1 after harvesting from the microcarriers 
at the various dO2 concentrations compared to pre-expansion (prior to expansion in the bioreactor) 
and post-harvest from the spinner flasks in a controlled environment cabinet with atmospheric air (~ 
100 % dO2). This comparison shows significantly higher (p < 0.05) outgrowth kinetics for BM-hMSCs 
across all controlled bioreactor expansion conditions including 100% dO2 compared to pre-expansion 
and post-harvest from the spinner flasks. In addition to this, BM-hMSCs cultured at 10 % dO2 
demonstrated significantly higher (p < 0.05) outgrowth kinetics compared to all other controlled dO2 
concentrations. These results suggest that the controlled (pH and dO2) expansion of BM-hMSCs on 
microcarriers in bioreactors at 100 % dO2 is having a positive impact on the outgrowth kinetics of BM-
hMSCs compared to the less-well controlled conditions in spinner flasks. In addition, for these cells, 
low dissolved oxygen concentrations further enhances that improvement.  
In accordance with the increase in outgrowth kinetics, the mean cell diameter of BM-hMSCs cultured 
in the controlled bioreactor conditions in figure 3B is significantly (p < 0.05) lower than pre-expansion 
and post-harvest from spinner flasks. The benefits to the manufacturing process of producing smaller 
BM-hMSCs has previously been discussed [33] and smaller cells are commonly associated with 
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increased proliferation, greater colony-forming efficiency and longer telomeres [34]. Likewise, BM-
hMSC culture at low dO2 from different sources may also display different functional characteristics 
and can modulate the autocrine or paracrine activity of a variety of cytokines and growth factors in 
BM-hMSCs [35]. The post-harvest colony-forming (CFU) efficiency of BM-hMSCs from the controlled 
bioreactor process at various dO2 concentrations can be seen in figure 3C, which shows a similar level 
of CFU efficiency for BM-hMSC harvested form 50 and 100 % dO2 conditions, compared with pre- and 
post- expansion spinner flask culture. In contrast, the post-harvest CFU efficiency of BM-hMSC from 
10 and 25 % dO2 was significantly higher (p < 0.05) than pre-expansion and post-harvest from spinner 
flasks. An increase in CFU efficiency of BM-hMSCs at low dissolved oxygen has previously been 
reported and has been shown to be independent of hypoxia inducible factor (HIF) expression in BM-
hMSCs [36].  
 
3.2 Controlled microcarrier expansion of BM-hMSC donors in serum-free 
Following the development of a process control strategy in FBS-based culture, it is important to assess 
the effect of this new control strategy on the serum-free (SFM) microcarrier expansion of multiple BM-
hMSC donors. A DO2 concentration of 25% was selected for the controlled expansion in SFM, due to 
the previous data that showed increased culture performance at low DO2 concentrations. Specifically, 
at DO2 concentration of 25% was selected over 10% DO2 due to the increased lactate production 
experienced at 10% DO2, which could be detrimental to the culture, particularly as the BM-hMSC 
density increases. Figure 4A shows the growth rate of the two donor BM-hMSC lines, BM-hMSC 1 and 
2, in controlled bioreactors in FBS and SFM, with a significantly increased growth rate for both BM-
hMSC donors in SFM to a final cell concentration of 7.11 ± 0.90 x 105 cell.mL-1 for BM-hMSC 1 and 6.13 
± 1.82 x 105 cell.mL-1 for BM-hMSC 2. This improvement represents a 300 % increase in the BM-hMSC 
yield across the two donors in SFM compared to that in FBS, which will be advantageous in driving 
cost-effective BM-hMSC manufacturing processes. The increase in growth kinetics in a controlled SFM 
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microcarrier process presented here is in accordance with our previously published data for monolayer 
culture [33] and uncontrolled spinner flask culture [8].  
 
The harvest efficiency of BM-hMSC from the FBS-based process was 91.5 ± 8.9 % across both donors, 
which is comparable to previous studies which demonstrated > 95% harvest efficiency for a spinner 
flask based harvesting process [22]. This result also demonstrates the effectiveness of the scalable 
harvesting method developed on sound engineering principals, as despite the change in bioreactor 
platform, maintaining the same detachment protocol for the DASbox bioreactor platform has yielded 
a similar BM-hMSC harvest efficiency [21] to that in spinner flasks. The overall harvest efficiency of the 
BM-hMSCs from the SFM process, however, was 76.5 ± 2.9 %, significantly lower than the previous 
FBS-based microcarrier processes. This drop is most likely due to the significantly increased BM-hMSC 
densities achieved under serum-free conditions, reducing the effectiveness of the separation process. 
Supplementary figure 3 shows that the harvest procedure employed has successfully removed the BM-
hMSCs from the microcarriers in the SFM process. Therefore, the reduction in harvest efficiency can 
be attributed to losses during the subsequent cell-microcarrier separation by filtration followed by cell 
concentration. This separation problem will clearly have to be addressed moving forward, as increased 
cell densities will be required in order to drive cost-effective manufacturing processes and harvesting 
efficiencies will have fundamental impact on final product yields [37]. Part of this success will be in 
developing scalable downstream technology, capable of reducing losses in the process step of 
separating the BM-hMSCs from the microcarriers after detachment [38].   
 
Metabolite analysis of the controlled bioreactor microcarrier culture of BM-hMSCs showed differences 
in the metabolic pathway usage relating to lactate and ammonia production between FBS-containing 
and serum-free cultures. Figure 4 shows the relative consumption of glucose (B), production of lactate 
(C) and ammonia (D), as well as the yield of lactate from glucose (E) in FBS and SFM for two donor BM-
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hMSC lines. In FBS-based expansion the consumption of glucose was 9.86 ± 1.49 pmol.cell-1.day-1 for 
BM-hMSC 1 and 8.37 ± 1.94 pmol.cell-1.day-1 for BM-hMSC 2, whereas for SFM expansion the 
consumption of glucose was significantly lower (p < 0.05) for both BM-hMSC donors with 4.41 ± 0.14 
pmol.cell-1.day-1 for BM-hMSC 1 and 3.54 ± 1.40 pmol.cell-1.day-1 for BM-hMSC 2. Similarly, the 
production of lactate in the controlled microcarrier process was significantly lower (p <0.05) in the 
SFM process compared to the FBS-based process for both donor BM-hMSC lines. This result is once 
again comparable to the levels of glucose and lactate flux measured during monolayer [33] and 
uncontrolled microcarrier culture [8] using the same donor BM-hMSCs. As with these previous studies, 
the production of ammonia is more similar between the FBS and SFM conditions indicating that the 
metabolite utilization under SFM conditions is more efficient, with a switch from energy production 
predominantly via anaerobic glycolysis in FBS culture to utilization of the oxidative phosphorylation 
pathway under SFM. The metabolite utilization between BM-hMSC donors is also more consistent in 
controlled SFM microcarrier culture, with a range in the yield of lactate from glucose between BM-
hMSC 1 and 2 of 0.12 mol.mol-1. In contrast, the yield of lactate from glucose in controlled FBS culture 
between donors showed a range of 1.32 mol.mol-1. This increase in consistency of BM-hMSC 
characteristics between donors in controlled SFM culture offers significant advantages for bioprocess 
development and has been maintained from monolayer culture of BM-hMSCs, demonstrating 
comparable process transfer throughout development.   
 
The concentrations of LDH and total protein for controlled bioreactor culture on microcarriers in FBS 
and SFM for two BM-hMSC donors can be seen in figure 5. The FBS-based process demonstrated little 
increase in LDH or total protein over the six days of culture, suggesting no significant cell damage is 
occurring during the expansion process. The total protein concentration in controlled SFM expansion 
also showed no significant increase over the six days of culture. However, the LDH concentration did 
see a slight increase on day six, when the cell density is at a maximum, up to the baseline level during 
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FBS culture. Considering that this occurs at increased BM-hMSC densities, this outcome should be 
evaluated as the final cell density of BM-hMSC bioreactor processes increase, to ensure that increasing 
the yield does not impact the quality of the product.    
 
It is evident from figure 6A that the attachment efficiency of BM-hMSCs in the bioreactor to the 
microcarriers is improved for both donors in the SFM expansion process, with > 75 % attachment 
efficiency after one day. In contrast, the FBS-based process had an attachment efficiency of < 70 % for 
both donors after one day, with a reduced attachment in the subsequent four days of expansion. This 
is likely due to the use of fibronectin to coat the microcarriers in the SFM process, which has been 
shown to improve cell attachment [39]. Given the implications of poor cell-microcarrier attachment 
described above, particularly as the process increases in scale, this higher level of attachment 
represents a key advantage of the SFM compared to the FBS-based microcarrier process. 
 
The specific outgrowth rate of BM-hMSCs from both the FBS and SFM controlled bioreactor processes 
can be seen in figure 6B which shows that the post-harvest outgrowth kinetics of BM-hMSC have been 
maintained. Figure 6C shows the post-harvest BM-hMSC diameter which has been significantly 
reduced (p < 0.05) compared to pre-expansion, which for the FBS process represented a reduction of 
2.1 µm for BM-hMSC 1 and 2.2 µm for BM-hMSC 2. This is in contrast to the uncontrolled spinner flask 
process presented previously [8] which demonstrated a slight increase in mean cell diameter of BM-
hMSC 1 .(1.2 µM) and BM-hMSC 2 (0.4 µm) between post-harvest and pre-expansion. The post-harvest 
colony-forming potential of the BM-hMSCs can be seen in figure 6D, which shows that the CFU 
potential has either increased or been maintained compared to pre-expansion. This is particularly 
apparent for the controlled FBS-based process, which showed a significant increase (p < 0.05) in the 
post-harvest CFU potential for both BM-hMSC donor lines. Verification of post-harvest 
immunophenotype and differential potential of BM-hMSCs used during this study can be seen in 
Supplementary Figure 4.  
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3.5 Process control to drive yield and consistency into BM-hMSC manufacture 
For these BM-hMSC therapies to successfully progress through to commercial production, the 
manufacturing cost of goods should be minimized, and the process robustness maximized throughout 
development. Driving yield and consistency into the BM-hMSC manufacturing process at an early stage 
of development will be critical to reduce the overall cost of goods and increase the cost-effectiveness 
of the final BM-hMSC product. Increasing the consistency of the final product will reduce process costs 
by demonstrating a level of control over the product and reducing the risk of batch failure. For large-
scale off the shelf processes, where the capital invested per batch is high, increasing the consistency 
of product quality will reduce the risk of product batch failures and significantly reduce the overall 
production costs.  This means that assessing the final BM-hMSC yield and donor consistency for various 
process iterations, would be highly informative on the direction of future manufacturing development. 
Currently, two of the key cost drivers for the production of off-the-shelf cell-based therapies are in the 
culture medium and the time it takes to manufacture a product batch in a facility [6]. Therefore, to 
make a basic yield comparison of each of the processes developed, the relative process yield in terms 
of number of BM-hMSCs produced as a function of the volume of culture medium and process time 
has been calculated for each of the controlled and uncontrolled systems.  
In addition to this process yield estimation, a combination of the inter- and intra-donor variation has 
been assessed to get an understanding of the relative consistency within each process.  The results of 
this can be seen in figure 7Error! Reference source not found., which demonstrates the increased 
process yield that is achieved in controlled SFM microcarrier culture. This improvement represents an 
increase in process yield of over 300 % for the SFM process compared to the FBS based process under 
the controlled conditions of the bioreactor. As the process scale increases and the manufacturing costs 
of the SFM are reduced, this improvement is likely to increase further, due to the issues associated 
with serum supply at a large-scale [40]. It can also be seen from figure 7 that the process yield is also 
increased by an average of around 500% for both donors under controlled conditions compared to the 
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poorly controlled expansion in spinner flasks, highlighting the importance of systematically developing 
a process control strategy to increase the yield of BM-hMSC production on microcarriers. It is 
important to note that the large difference in process yield between monolayer and microcarrier 
culture at the bench-scale evaluated here, will increase as the scale increases, due to the improved 
economies of scale achievable in a suspension bioreactor-based process. 
The percentage coefficient of variation has been calculated for each of the expansion processes to 
assess the relative amount of variation in cell yield between each condition. This parameter is a 
combination of inter-donor variation, (the variation between each donor) and intra-donor variation 
(the variation between batch runs of each donor), as seen in figure 7, which shows the lowest 
coefficient of variation for the controlled SFM microcarrier process with 14.7 %. A coefficient of 
variation of 15 % or less is in alignment with the established regulatory guidance [41, 42], 
demonstrating control over the product. There is also a clear difference between the controlled and 
uncontrolled processes in FBS, with process control reducing the coefficient of variation from 79.1 % 
for the spinner flask to 37.5 % for the bioreactor experiments. In addition to the scalability of stirred-
tank bioreactors versus alternative BM-hMSC culture technology, this further demonstrates that 
stirred-tank bioreactors can achieve effective process control across a number of process parameters, 
utilizing online and non-destructive methods to maintain the process in a state of control for the 
duration of the culture.  This outcome represents a significant reduction in process variation, via the 
introduction of a process control system, once again demonstrating the importance of developing a 
process control strategy for BM-hMSC production.       
Conclusions 
The systematic development of a process control strategy in a stirred-tank bioreactor for the 
microcarrier expansion of BM-hMSCs has significantly increased the yield and consistency achievable 
in the process compared to the relatively-uncontrolled conditions in a spinner flask. Even operating 
the microcarrier expansion process for BM-hMSCs in closed system with controlled pH and at 100 % 
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dO2, has demonstrated improved growth and post-harvest BM-hMSC quality characteristics compared 
to those produced from a spinner flask in atmospheric air in biological safety cabinets.  
 
Studies looking at the effect of exposing cells grown at low dissolved oxygen (“hypoxic”) conditions 
during bioreactor culture to atmospheric conditions during the culture period, as can occur during 
media exchange, etc., has highlighted the importance of operating closed and controlled processes to 
avoid large fluctuation of the dissolved oxygen concentration of the medium. Thus, for closed 
conditions for these donor cells grown at 10 and 25 % dO2 in FBS-based medium, a further 
improvement was achieved compared to 100 % dO2.  
 
The introduction of serum-free medium into such controlled low dO2 conditions has further increased 
the yield across two BM-hMSC donors, however, with reduced harvest efficiency compared to the FBS-
based process that has lower cell numbers at harvest. It is argued that this drop was primarily due to 
cell losses in the cell-microcarrier separation step (filtration). Thus, it will be imperative to develop 
specific downstream technology to effectively separate the cells from the microcarriers, especially as 
the number of BM-hMSCs per volume is increased under serum-free conditions. 
 
The development of a process control strategy has significantly increased the yield and consistency 
between BM-hMSC donors with a coefficient of variance between and within these donors under 
serum-free conditions of less than 15 %. This increase in consistency is in conjunction with a significant 
increase in the BM-hMSCs produced per volume of medium per unit time under serum-free 
conditions, which will be critical in increasing the economies of scale and reducing the cost of BM-
hMSC therapies. Furthermore, the introduction of the process control strategy has significantly 
reduced the BM-hMSC inter- and intra-donor variation in FBS-based culture from 79.1 to 37.5 %, which 
will be critical for the future development of both patient-specific and off-the-shelf BM-hMSC 
manufacturing processes.     
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Figures 
Figure 1 – Implications of exposing low dissolved oxygen (dO2) cultures (5% dO2 and 25% dO2) in a 
biological safety cabinet to normal atmospheric conditions for 1, 5 and 60 minutes. Demonstrating 
the importance of continuous closed process control during bioreactor culture. Bars represent the 
set-point recovery time to 5 or 25% dO2 and diamonds represent the maximum dO2 concentration 
reached during each exposure and recovery period. 
 
Figure 2 – Effect of dissolved oxygen (dO2) on BM-hMSC 1 growth over six days of culture in FBS-
containing medium in the DASbox controlled bioreactor, showing increased cell numbers over six 
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days at lower dissolved oxygen concentrations (A) pre-harvest, (B) post-harvest, (C) per cell flux of 
ammonia and (D) yield of lactate from glucose. Control set-points are 115rpm impeller speed and pH 
7.4 with headspace aeration. Data shows mean ± SD, n = 3. * denotes a significant difference (p < 
0.05) compared to 100% DO2.  
 
Figure 3 –  Post-harvest characteristics of BM-hMSC 1 from controlled microcarrier culture in FBS-
containing medium compared to pre-expansion and post-harvest from spinner flasks in a controlled 
environment cabinet with atmospheric air ( ~ 100 % dO2). Showing (A) increased outgrowth rate; (B) 
reduced mean cell diameter; and (C) increased CFU efficiency at reduced dO2 concentrations in the 
bioreactor and improved performance at all dO2 concentrations compared to the spinner flasks. Data 
shows mean ± SD, n = 3. * denotes a significant difference (p < 0.05) compared to pre-expansion and 
post-spinners.        
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Figure 4 – Comparison of culture on microcarriers in the bioreactor in FBS and SFM across the two 
BM-hMSC donors at 115rpm, with controlled 25% dO2 by headspace aeration and a pH of 
7.4.Showing (A) increased growth rate for both donors in SFM, (B) reduced glucose consumption in 
SFM, (C) reduced lactate production in SFM, (D) reduced ammonia production in SFM and (E) yield of 
lactate from glucose. Data shows mean ± SD, n = 3. * denotes a significant difference (p < 0.05) 
compared with the same BM-hMSCs in FBS-containing medium.   
 
Figure 5 – Comparison of culture on microcarriers in the bioreactor in FBS and SFM across two BM-
hMSC donors at 115rpm, with controlled 25% dO2 by headspace aeration and a pH of 7.4. Showing 
(A) no increase in total protein concentration over six days and (B) increased LDH concentration at 
the end of SFM culture. Data shows mean ± SD, n = 3.  
 
Figure 6 – Attachment rate and post-harvest characteristics during culture on microcarriers in the 
bioreactor in FBS and SFM across two BM-hMSC donors at 115rpm, with controlled 25% dO2 by 
headspace aeration and a pH of 7.4. Showing (A) increased cell attachment to microcarriers in SFM, 
(B) increased outgrowth rate in SFM, (C) reduced mean cell diameter and (D) maintained CFU 
efficiency post-harvest. Data shows mean ± SD, n = 3. * denotes a significant difference (p < 0.05) 
compared with the same BM-hMSCs pre-expansion.  
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Figure 7 – Impact of process control on the process yield from a microcarrier expansion process at 
25% dO2 in the bioreactor compared poorly controlled monolayer and spinner flask culture under 
atmospheric conditions. Showing the controlled bioreactor process under serum-free conditions 
provides a much higher yield and more consistency between donors. Bars denote process yield in 
terms of number of cells produced per volume of medium per unit time and the line chart denotes 
the coefficient of variation between and within donor batch runs.  
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